experimental demyelination
Recently Published Documents


TOTAL DOCUMENTS

66
(FIVE YEARS 6)

H-INDEX

26
(FIVE YEARS 1)

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Darpan Saraswat ◽  
Hani J. Shayya ◽  
Jessie J. Polanco ◽  
Ajai Tripathi ◽  
R. Ross Welliver ◽  
...  

AbstractChronic demyelination in the human CNS is characterized by an inhibitory microenvironment that impairs recruitment and differentiation of oligodendrocyte progenitor cells (OPCs) leading to failed remyelination and axonal atrophy. By network-based transcriptomics, we identified sulfatase 2 (Sulf2) mRNA in activated human primary OPCs. Sulf2, an extracellular endosulfatase, modulates the signaling microenvironment by editing the pattern of sulfation on heparan sulfate proteoglycans. We found that Sulf2 was increased in demyelinating lesions in multiple sclerosis and was actively secreted by human OPCs. In experimental demyelination, elevated OPC Sulf1/2 expression directly impaired progenitor recruitment and subsequent generation of oligodendrocytes thereby limiting remyelination. Sulf1/2 potentiates the inhibitory microenvironment by promoting BMP and WNT signaling in OPCs. Importantly, pharmacological sulfatase inhibition using PI-88 accelerated oligodendrocyte recruitment and remyelination by blocking OPC-expressed sulfatases. Our findings define an important inhibitory role of Sulf1/2 and highlight the potential for modulation of the heparanome in the treatment of chronic demyelinating disease.


2020 ◽  
Vol 14 (10) ◽  
pp. 1449-1464 ◽  
Author(s):  
Mahsa Motavaf ◽  
Majid Sadeghizadeh ◽  
Sadegh Babashah ◽  
Leila Zare ◽  
Mohammad Javan

2020 ◽  
Vol 343 ◽  
pp. 577227
Author(s):  
María Nazareth González-Alvarado ◽  
Caroline Rötger ◽  
Laura Berger ◽  
Barry London ◽  
Stefanie Haase ◽  
...  

2020 ◽  
Author(s):  
Darpan Saraswat ◽  
Hani J. Shayya ◽  
Jessie J. Polanco ◽  
Ajai Tripathi ◽  
R. Ross Welliver ◽  
...  

Chronic demyelination in the human CNS is characterized by an inhibitory microenvironment that impairs recruitment and differentiation of oligodendrocyte progenitor cells (OPCs) leading to failed remyelination and axonal atrophy. By network-based transcriptomics, we identified sulfatase 2 (Sulf2) mRNA in activated human primary OPCs. Sulf2, an extracellular endosulfatase, modulates the signaling microenvironment by editing the pattern of sulfation on heparan sulfate proteoglycans. We found that Sulf2 was increased in demyelinating lesions in multiple sclerosis and was actively secreted by human OPCs. In experimental demyelination, elevated OPC Sulf1/2 expression directly impaired progenitor recruitment and subsequent generation of oligodendrocytes thereby limiting remyelination. Sulf1/2 potentiates the inhibitory microenvironment by promoting BMP and WNT signaling in OPCs. Importantly, pharmacological sulfatase inhibition using PI-88 accelerated oligodendrocyte recruitment and remyelination by blocking OPC-expressed sulfatases. Our findings define an important inhibitory role of Sulf1/2 and highlight the potential for modulation of the heparanome in the treatment of chronic demyelinating disease.


2019 ◽  
Vol 31 (1) ◽  
pp. 89-99 ◽  
Author(s):  
Hans-Gert Bernstein ◽  
Gerburg Keilhoff ◽  
Henrik Dobrowolny ◽  
Paul C. Guest ◽  
Johann Steiner

Abstract Perineuronal oligodendrocytes (pn-Ols) are located in the cerebral gray matter in close proximity to neuronal perikarya and less frequently near dendrites and neurites. Although their morphology is indistinguishable from that of other oligodendrocytes, it is not known if pn-Ols have a similar or different cell signature from that of typical myelinating oligodendroglial cells. In this review, we discussed the potential roles of these cells in myelination under normal and pathophysiologic conditions as functional and nutritional supporters of neurons, as restrainers of neuronal firing, and as possible players in glutamate-glutamine homeostasis. We also highlighted the occurrences in which perineuronal oligodendroglia are altered, such as in experimental demyelination, multiple sclerosis, cerebral ischemia, epilepsy, Alzheimer’s disease, schizophrenia, major depression, and bipolar disorder.


2018 ◽  
Vol 9 ◽  
Author(s):  
Nellie A. Martin ◽  
Viktor Molnar ◽  
Gabor T. Szilagyi ◽  
Maria L. Elkjaer ◽  
Arkadiusz Nawrocki ◽  
...  

2015 ◽  
Vol 53 (7) ◽  
pp. 4905-4917 ◽  
Author(s):  
René Große-Veldmann ◽  
Birte Becker ◽  
Sandra Amor ◽  
Paul van der Valk ◽  
Cordian Beyer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document